Company news

Zealand Pharma A/S news in 2025

Zealand Pharma A/S's news releases, calls and decks from 2025, newest first.

View company

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025

December 31, 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

December 11, 2025

Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

December 11, 2025

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025

December 1, 2025

Zealand Pharma Announces Financial Results for the First Nine Months of 2025

November 13, 2025

Zealand Pharma to participate in the Jefferies Global Healthcare Conference

November 12, 2025

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

November 6, 2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

October 17, 2025

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025

September 30, 2025

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations

September 24, 2025

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

September 11, 2025

Zealand Pharma to participate in upcoming investor conferences in September 2025

August 28, 2025

Zealand Pharma Announces Financial Results for the First Half of 2025

August 14, 2025

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

August 7, 2025

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

June 30, 2025

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

June 18, 2025

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

June 2, 2025

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

May 19, 2025

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

May 12, 2025

Zealand Pharma announces closing of collaboration and license agreement with Roche

May 9, 2025

Zealand Pharma Announces Financial Results for the First Three Months of 2025

May 8, 2025

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

May 1, 2025

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

April 24, 2025

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

April 23, 2025

Calls in 2025

Decks in 2025